佐力药业(300181) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥340,156,986.02, representing a 76.07% increase compared to ¥193,188,846.44 in the same period last year[9]. - Net profit attributable to shareholders reached ¥43,795,349.24, a significant increase of 300.98% from ¥10,922,165.26 in the previous year[9]. - Basic earnings per share rose to ¥0.0720, up 302.23% from ¥0.0179 in the same period last year[9]. - The company's operating revenue for the reporting period was 340.16 million yuan, an increase of 76.07% compared to the same period last year, driven by effective marketing strategies and improved production management[28]. - Net profit attributable to shareholders was 43.80 million yuan, a year-on-year increase of 300.98%, primarily due to significant growth in operating profit[28]. - Operating profit for the current period was ¥54,330,204.00, up from ¥12,451,504.52 in the previous period, showing an increase of approximately 336.5%[71]. - The total comprehensive income for the current period was ¥164,159,849.35, significantly higher than ¥11,225,886.49 in the previous period[75]. Cash Flow - The net cash flow from operating activities was ¥47,608,885.33, a remarkable turnaround from a negative cash flow of ¥64,940.40 in the same period last year, marking a 73,411.66% increase[9]. - Cash inflow from operating activities totals 361,862,270.26, compared to 216,933,673.34 in the previous period, reflecting an increase of about 67%[87]. - Cash inflow from investment activities is 82,884,423.28, compared to 17,305,966.49 in the previous period, showing a substantial increase of approximately 378%[87]. - The net cash flow from investment activities is 15,054,267.34, improving from a negative cash flow of -23,228,446.85 in the previous period[87]. - Cash inflow from financing activities is 149,096,000.00, compared to 89,246,900.00 in the previous period, indicating an increase of about 67%[89]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,654,065,874.62, reflecting a 7.46% increase from ¥2,469,876,379.74 at the end of the previous year[9]. - The total liabilities increased to ¥418,230,218.83 from ¥411,997,700.82, reflecting a growth of about 4.0%[63]. - Current liabilities decreased to CNY 558,144,160.49 from CNY 599,042,707.35, a reduction of approximately 6.8%[53]. - Total liabilities rose from $750,429,212.25 to $773,316,330.32, marking an increase of about 3.0%[100]. - The company's total equity remained stable at $1,719,447,167.49, indicating no change during the reporting period[100]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,609[13]. - The largest shareholder, Yu Youqiang, held 21.34% of the shares, amounting to 129,890,463 shares[13]. - The company's equity attributable to shareholders rose to CNY 1,754,914,318.23, up from CNY 1,602,812,556.70, indicating an increase of around 9.5%[56]. Market Strategy and Risks - The company plans to continue focusing on marketing and internal management to sustain growth in the upcoming periods[28]. - The company is closely monitoring industry policy changes and will optimize production processes and improve product quality to enhance market competitiveness[32]. - The company has identified risks associated with drug research and development, emphasizing the need for careful project selection and effective risk management mechanisms[33]. - The company confirmed significant goodwill from acquisitions, which poses a risk of impairment if the acquired entities do not perform well[33]. - The company is actively expanding its market presence through new channels such as "Internet+" and e-commerce, while controlling costs and expenses[32].